Beyond Eli Lilly: what holds Indiana's $100 billion life sciences sector together

Indiana's life sciences sector crossed $100 billion in 2025 and now employs roughly 70,000 people, according to a sponsored feature in Genetic Engineering News. The state is treating the number as proof that it has built a real biopharma cluster on par with Boston and the Bay Area. The harder question is whether the rest of the ecosystem can carry the weight when the anchor tenant, Eli Lilly, stops expanding.

A "biopharma cluster," in plain terms, is a region where drug discovery, clinical trials, manufacturing, and the companies that supply them all sit close enough to feed one another. Indiana's version of that includes Eli Lilly in Indianapolis, the contract manufacturer Catalent (now part of Novo Holdings), the animal health company Elanco, and a long tail of diagnostics, medical device, and plant science firms. The state's economic development pitch groups all of it under "life sciences," a term that covers anything from a pill to a pregnancy test to a cancer therapy that carries a radioactive payload directly to a tumor.

The $100 billion figure comes from a paid placement, not an independent audit. A separate, academic estimate from the Indiana Business Research Center's summer 2026 analysis sizes the life sciences cluster at $82 billion. The two numbers are not necessarily contradictory. Sponsored content tends to count gross activity across the wider sector, while IBRC's $82 billion tracks a narrower cluster definition. The gap is a reminder that the milestone is partly a measurement choice, and any reader comparing Indiana to other states should ask which definition the other state is using.

Even at $82 billion, Indiana is in the conversation. What the available reporting does not give the reader is a clean head-to-head: independent state-level comparisons on NIH dollars, venture funding, and FDA approvals are not in the public record cited here. That absence is itself informative. The state's $100 billion claim is anchored on output and employment, the metrics a manufacturing-heavy inland cluster can lead on, not on the innovation-input metrics where Boston, the Bay Area, and North Carolina's Research Triangle dominate. Inside Indiana Business frames the state's renewed university tech transfer push as the lever meant to close that gap.

That lever matters because Lilly, headquartered in Indianapolis since 1876, is the load-bearing column. Its GLP-1 drugs, Mounjaro and Zepbound, are driving a multi-year manufacturing buildout that pulls in construction workers, engineers, and suppliers across the state. BioSpace's March 2026 profile and VectorTA's Indianapolis ecosystem piece both document the spillover into contract manufacturing, lab space, and adjacent services. Take Lilly out of the math and the cluster's center of gravity shifts sharply. Most independent reporting on the sector still treats Indianapolis as a Lilly town with a growing, but thinner, supporting cast.

The "next generation" capabilities the sponsored piece highlights, including AI-driven drug discovery, radiopharmaceuticals, and advanced pharmaceutical manufacturing, are real bets, but each is still small relative to the Lilly footprint. Purdue University, which ranks seventh nationally for U.S. patents received, is the state's most credible pipeline for the AI and computational medicine layer, with a particular strength in small-molecule discovery, the kind of traditional chemistry that produced most of today's pills. InContext traces how the state has tried to broaden that pipeline into animal health and plant science, where Elanco and Corteva anchor a separate, durable cluster.

The honest answer to the headline question is that Indiana has built a real, broad-based life sciences economy whose growth rate and headline numbers still lean heavily on a single company's decision to keep spending on U.S. capacity. If Lilly's GLP-1 capex peaks and holds, the cluster's durability will turn on whether non-Lilly employment, patents, and FDA approvals keep rising without that tailwind. The benchmark worth tracking is not the next $100 billion headline but the year non-Lilly activity outpaces Lilly-adjacent activity in the state tally.